Javier Alonso

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5404975/publications.pdf

Version: 2024-02-01

75 papers	2,685 citations	201385 27 h-index	205818 48 g-index
80 all docs	80 docs citations	80 times ranked	4300 citing authors

#	Article	IF	Citations
1	Sarcoma classification by DNA methylation profiling. Nature Communications, 2021, 12, 498.	5.8	237
2	Periostin: A Matricellular Protein With Multiple Functions in Cancer Development and Progression. Frontiers in Oncology, 2018, 8, 225.	1.3	195
3	Common variants near TARDBP and EGR2 are associated with susceptibility to Ewing sarcoma. Nature Genetics, 2012, 44, 323-327.	9.4	160
4	Chimeric EWSR1-FLI1 regulates the Ewing sarcoma susceptibility gene EGR2 via a GGAA microsatellite. Nature Genetics, 2015, 47, 1073-1078.	9.4	157
5	Endothelial Cytosolic Proteins Bind to the 3â€² Untranslated Region of Endothelial Nitric Oxide Synthase mRNA: Regulation by Tumor Necrosis Factor Alpha. Molecular and Cellular Biology, 1997, 17, 5719-5726.	1.1	133
6	RB1 gene mutation up-date, a meta-analysis based on 932 reported mutations available in a searchable database. BMC Genetics, 2005, 6, 53.	2.7	127
7	Primary intracranial spindle cell sarcoma with rhabdomyosarcoma-like features share a highly distinct methylation profile and DICER1 mutations. Acta Neuropathologica, 2018, 136, 327-337.	3.9	104
8	DAX1, a direct target of EWS/FLI1 oncoprotein, is a principal regulator of cell-cycle progression in Ewing's tumor cells. Oncogene, 2008, 27, 6034-6043.	2.6	100
9	The orphan nuclear receptor DAX1 is up-regulated by the EWS/FLI1 oncoprotein and is highly expressed in Ewing tumors. International Journal of Cancer, 2006, 118, 1381-1389.	2.3	75
10	Cholecystokinin Down-Regulation by RNA Interference Impairs Ewing Tumor Growth. Clinical Cancer Research, 2007, 13, 2429-2440.	3.2	75
11	Array CGH and gene-expression profiling reveals distinct genomic instability patterns associated with DNA repair and cell-cycle checkpoint pathways in Ewing's sarcoma. Oncogene, 2008, 27, 2084-2090.	2.6	62
12	DNA methylation-based reclassification of olfactory neuroblastoma. Acta Neuropathologica, 2018, 136, 255-271.	3.9	59
13	Efficacy of ATR inhibitors as single agents in Ewing sarcoma. Oncotarget, 2016, 7, 58759-58767.	0.8	59
14	Spectrum of germline RB1 gene mutations in Spanish retinoblastoma patients: Phenotypic and molecular epidemiological implications. Human Mutation, 2001, 17, 412-422.	1.1	55
15	Genome-wide association study identifies multiple new loci associated with Ewing sarcoma susceptibility. Nature Communications, 2018, 9, 3184.	5.8	50
16	EWS/FLI1 Target Genes and Therapeutic Opportunities in Ewing Sarcoma. Frontiers in Oncology, 2015, 5, 162.	1.3	46
17	EWS-FLI1 perturbs MRTFB/YAP-1/TEAD target gene regulation inhibiting cytoskeletal autoregulatory feedback in Ewing sarcoma. Oncogene, 2017, 36, 5995-6005.	2.6	46
18	DNA Methylomes Reveal Biological Networks Involved in Human Eye Development, Functions and Associated Disorders. Scientific Reports, 2017, 7, 11762.	1.6	44

#	Article	IF	Citations
19	The EWS/FLI1 oncogenic protein inhibits expression of the Wnt inhibitor DICKKOPF-1 gene and antagonizes Î²-catenin/TCF-mediated transcription. Carcinogenesis, 2010, 31, 394-401.	1.3	40
20	Aspirin-Stimulated Nitric Oxide Production by Neutrophils After Acute Myocardial Ischemia in Rabbits. Circulation, 1996, 94, 83-87.	1.6	40
21	Lysyl Oxidase Is Downregulated by the EWS/FLI1 Oncoprotein and Its Propeptide Domain Displays Tumor Supressor Activities in Ewing Sarcoma Cells. PLoS ONE, 2013, 8, e66281.	1.1	39
22	Severe alpha-1 antitrypsin deficiency in composite heterozygotes inheriting a new splicing mutation QOMadrid. Respiratory Research, 2014, 15, 125.	1.4	38
23	Search for mutations of thehRAD54 gene in sporadic meningiomas with deletion at 1p32. , 1999, 24, 300-304.		35
24	Regulation of the MicroRNA Processor DGCR8 by the Tumor Suppressor ING1. Cancer Research, 2010, 70, 1866-1874.	0.4	34
25	Familial retinoblastoma due to intronic LINE-1 insertion causes aberrant and noncanonical mRNA splicing of the RB1 gene. Journal of Human Genetics, 2016, 61, 463-466.	1.1	33
26	The First European Interdisciplinary Ewing Sarcoma Research Summit. Frontiers in Oncology, 2012, 2, 54.	1.3	32
27	A Microsatellite Fluorescent Method for Linkage Analysis in Familial Retinoblastoma and Deletion Detection at the RB1 Locus in Retinoblastoma and Osteosarcoma. Diagnostic Molecular Pathology, 2001, 10, 9-14.	2.1	30
28	Evidence That an Endothelial Cytosolic Protein Binds to the 3â€²-Untranslated Region of Endothelial Nitric Oxide Synthase mRNA. Journal of Vascular Research, 1999, 36, 201-208.	0.6	29
29	EWS-FLI1-mediated suppression of the RAS-antagonist Sprouty 1 (SPRY1) confers aggressiveness to Ewing sarcoma. Oncogene, 2017, 36, 766-776.	2.6	29
30	Endothelin-1 Upregulation in the Kidney of Uninephrectomized Spontaneously Hypertensive Rats and Its Modification by the Angiotensin-Converting Enzyme Inhibitor Quinapril. Hypertension, 1997, 29, 1178-1185.	1.3	29
31	Implications of a RAD54L polymorphism (2290C/T) in human meningiomas as a risk factor and/or a genetic marker. BMC Cancer, 2003, 3, 6.	1.1	27
32	Comparison of different techniques for the detection of genetic risk-identifying chromosomal gains and losses in neuroblastoma. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2008, 453, 47-55.	1.4	25
33	Targeting DAX-1 in embryonic stem cells and cancer. Expert Opinion on Therapeutic Targets, 2010, 14, 169-177.	1.5	25
34	DNA methylation profiling identifies PTRF/Cavin-1 as a novel tumor suppressor in Ewing sarcoma when co-expressed with caveolin-1. Cancer Letters, 2017, 386, 196-207.	3.2	25
35	Identification of 26 new constitutionalRB1gene mutations in Spanish, Colombian, and Cuban retinoblastoma patients. Human Mutation, 2005, 25, 99-99.	1.1	24
36	Exome array analysis identifies ETFB as a novel susceptibility gene for anthracycline-induced cardiotoxicity in cancer patients. Breast Cancer Research and Treatment, 2018, 167, 249-256.	1.1	23

#	Article	IF	Citations
37	Gene expression and immunohistochemical analyses identify SOX2 as major risk factor for overall survival and relapse in Ewing sarcoma patients. EBioMedicine, 2019, 47, 156-162.	2.7	23
38	Exome array analysis identifies GPR35 as a novel susceptibility gene for anthracycline-induced cardiotoxicity in childhood cancer. Pharmacogenetics and Genomics, 2017, 27, 445-453.	0.7	22
39	EWS-FLI1 confers exquisite sensitivity to NAMPT inhibition in Ewing sarcoma cells. Oncotarget, 2017, 8, 24679-24693.	0.8	20
40	SpainUDP: The Spanish Undiagnosed Rare Diseases Program. International Journal of Environmental Research and Public Health, 2018, 15, 1746.	1.2	19
41	Hippo pathway effectors YAP1/TAZ induce an EWSâ€“FLI1â€opposing gene signature and associate with disease progression in Ewing sarcoma. Journal of Pathology, 2020, 250, 374-386.	2.1	19
42	Five new cases of syndromic intellectual disability due to KAT6A mutations: widening the molecular and clinical spectrum. Orphanet Journal of Rare Diseases, 2020, 15, 44.	1.2	18
43	Frequency of low-level and high-level mosaicism in sporadic retinoblastoma: genotypeâ€“phenotype relationships. Journal of Human Genetics, 2020, 65, 165-174.	1.1	16
44	Therapeutic Potential of EWSR1â€“FLI1 Inactivation by CRISPR/Cas9 in Ewing Sarcoma. Cancers, 2021, 13, 3783.	1.7	15
45	Glomerular up-regulation of EIIIA and V120 fibronectin isoforms in proliferative immune complex nephritis. Kidney International, 1996, 50, 908-919.	2.6	13
46	Pathogenic validation of unique germline intronic variants ofRB1 in retinoblastoma patients using minigenes. Human Mutation, 2007, 28, 1245-1245.	1.1	13
47	Devazepide, a nonpeptide antagonist of CCK receptors, induces apoptosis and inhibits Ewing tumor growth. Anti-Cancer Drugs, 2009, 20, 527-533.	0.7	13
48	High-throughput RNAi screen in Ewing sarcoma cells identifies leucine rich repeats and WD repeat domain containing 1 (LRWD1) as a regulator of EWS-FLI1 driven cell viability. Gene, 2017, 596, 137-146.	1.0	13
49	The role of miR-17-92 in the miRegulatory landscape of Ewing sarcoma. Oncotarget, 2017, 8, 10980-10993.	0.8	13
50	Two new mutations and three novel polymorphisms in the RB1 gene in Ecuadorian patients. Journal of Human Genetics, 2003, 48, 639-641.	1.1	12
51	DICER1 mutation and tumors associated with a familial tumor predisposition syndrome: practical considerations. Familial Cancer, 2017, 16, 291-294.	0.9	12
52	Fibronectin (FN) decreases glomerular lesions and synthesis of tumour necrosis factor-alpha (TNF-Î±), platelet-activating factor (PAF) and FN in proliferative glomerulonephritis. Clinical and Experimental Immunology, 1995, 101, 334-340.	1.1	11
53	EWSâ€FLI1 impairs aryl hydrocarbon receptor activation by blocking tryptophan breakdown via the kynurenine pathway. FEBS Letters, 2016, 590, 2063-2075.	1.3	11
54	Therapeutic targeting of the PLK1-PRC1-axis triggers cell death in genomically silent childhood cancer. Nature Communications, 2021, 12, 5356.	5.8	11

#	Article	IF	Citations
55	Identification of genetic variants in pharmacokinetic genes associated with Ewing Sarcoma treatment outcome. Annals of Oncology, 2016, 27, 1788-1793.	0.6	10
56	Potential Factors Governing Extracellular Matrix Production by Mesangial Cells: Their Relevance for the Pathogenesis of IgA Nephropathy1. Contributions To Nephrology, 1995, 111, 45-54.	1.1	9
57	Low-frequency variation near common germline susceptibility loci are associated with risk of Ewing sarcoma. PLoS ONE, 2020, 15, e0237792.	1.1	6
58	Involvement of Lipid Mediators in the Pathogenesis of Experimental Nephrosis in Rats: Its Pharmacological Modulation. Renal Failure, 1991, 13, 95-101.	0.8	5
59	De novo small deletion affecting transcription start site of short isoform of <scp>AUTS2</scp> gene in a patient with syndromic neurodevelopmental defects. American Journal of Medical Genetics, Part A, 2021, 185, 877-883.	0.7	5
60	Five novel single nucleotide polymorphisms of the RB1 gene (g.5625T>C, g.70169T>G, g.76875A>T,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	1.1	4
61	New RB1 oncogenic mutations and intronic polymorphisms in Serbian retinoblastoma patients: genetic counseling implications. Journal of Human Genetics, 2006, 51, 909-913.	1.1	4
62	Low penetrance hereditary retinoblastoma in a family: what should we consider in the genetic counselling process and follow up?. Familial Cancer, 2011, 10, 617-621.	0.9	4
63	The Transcription Factor FEZF1, a Direct Target of EWSR1-FLI1 in Ewing Sarcoma Cells, Regulates the Expression of Neural-Specific Genes. Cancers, 2021, 13, 5668.	1.7	4
64	CD44 In Sarcomas: A Comprehensive Review and Future Perspectives. Frontiers in Oncology, 0, 12, .	1.3	4
65	A novel complex mutation in exon 8 of RB1 in a case of isolated bilateral retinoblastoma. Human Mutation, 2000, 15, 583-583.	1.1	2
66	Helpful Criteria When Implementing NGS Panels in Childhood Lymphoblastic Leukemia. Journal of Personalized Medicine, 2020, 10, 244.	1.1	1
67	Comparison of variant calling methods in exome sequencing of matched tumor-normal sample pairs. EMBnet Journal, 2013, 19, 62.	0.2	1
68	Molecular Approaches to Diagnosis in Ewing Sarcoma: RT-PCR. Methods in Molecular Biology, 2021, 2226, 85-103.	0.4	1
69	Two independentRB1-inactivating mutations in peripheral blood DNA of a hereditary retinoblastoma patient. Genes Chromosomes and Cancer, 2004, 40, 271-275.	1.5	0
70	DAX1 is a direct target of EWS/FLI1 oncoprotein and a principal regulator of cell cycle progression in Ewing tumor cells. European Journal of Cancer, Supplement, 2008, 6, 34.	2.2	0
71	Abstract A40: Epigenomic profiling identifies NCRNAs as novel tumor suppressors in developmental tumors. Cancer Research, 2016, 76, A40-A40.	0.4	0
72	Abstract A18: Epigenetic profiling uncovers the suppressive role of caveolae in Ewing sarcoma. , 2016, , .		0

#	Article	IF	Citations
73	Abstract 3508: EWS-FLI1 represses Rho-actin signaling via MRTFB/YAP-1/TEAD perturbation in Ewing Sarcoma. , 2017, , .		0
74	Abstract 2970: Multiple new susceptibility loci identified in genome-wide association study of Ewing sarcoma. , 2018, , .		0
75	Abstract A13: Genome-wide association study identifies multiple new loci associated with Ewing sarcoma susceptibility. , 2018, , .		0